Quetmolimab - EA Pharma/Eisai Co Ltd
Alternative Names: E-6011; KANAb 001Latest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator KAN Research Institute
- Developer EA Pharma; Eisai Co Ltd
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Chemokine CX3CL1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Primary biliary cirrhosis; Rheumatoid arthritis
Most Recent Events
- 03 Apr 2024 EA Pharma completed the Phase-II for Crohn's disease in Czech Republic, Russia, Hungary, Poland, Japan (IV), (NCT03733314)
- 20 May 2022 Discontinued - Phase-II for Crohn's disease in Czech Republic, Russia Hungary, Poland, Japan (IV), due to business priorities (EA Pharma, Eisai Co Ltd pipeline, May 2022)
- 04 Aug 2021 Discontinued - Phase-II for Rheumatoid arthritis (Adjunctive treatment) in Japan, prior to August 2021 (SC)